Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURV-SEP: Dimethyl Fumarate in Multiple Sclerosis
NCT02901106Phase 4Terminated
- Sponsor
- Adolphe de Rothschild Foundation Hospital
- Start
- May 2017
- Primary completion
- Oct 2017
- Countries
- 1
01
Overview
Phase 4, open-label trial of dimethyl fumarate in multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS), sponsored by Adolphe de Rothschild Foundation Hospital. Primary endpoint: Number of patients with a relapse and/or progressive worsening of disease (EDSS score) at 1 year. Started May 2017; status: terminated.
02
Drugs
dimethyl fumarate
03
Conditions
multiple sclerosis (MS)primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on NCT02901106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02901106.